{"id":"placebo-liraglutide","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4084119","moleculeType":"Protein","molecularWeight":"3751.26"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Placebo-liraglutide refers to an inert comparator arm in clinical studies of liraglutide, the active GLP-1 receptor agonist. It contains no pharmacologically active ingredient and serves as a control to isolate the true therapeutic effects of liraglutide from placebo response. This is a research tool rather than a therapeutic agent.","oneSentence":"This is a placebo control formulation used in clinical trials to compare against liraglutide's active GLP-1 receptor agonist effects.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:01:05.555Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT05681299","phase":"PHASE4","title":"Effects of GH and Lirglutide on AgRP","status":"RECRUITING","sponsor":"Columbia University","startDate":"2023-05-01","conditions":"Healthy, Growth Hormone Deficiency","enrollment":40},{"nctId":"NCT04775082","phase":"PHASE3","title":"SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2021-03-04","conditions":"Obesity","enrollment":78},{"nctId":"NCT07225829","phase":"PHASE2","title":"A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis","status":"RECRUITING","sponsor":"4Moving Biotech","startDate":"2025-06-17","conditions":"Knee Osteoarthritis, Synovitis of Knee","enrollment":129},{"nctId":"NCT06976619","phase":"PHASE2","title":"The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-10-03","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":60},{"nctId":"NCT03260881","phase":"PHASE4","title":"Liraglutide Effects on Epicardial Fat Inflammatory Genes","status":"COMPLETED","sponsor":"University of Miami","startDate":"2018-09-01","conditions":"Type2 Diabetes, Coronary Artery Disease","enrollment":38},{"nctId":"NCT05419856","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee","status":"COMPLETED","sponsor":"4Moving Biotech","startDate":"2022-08-09","conditions":"Knee Osteoarthritis","enrollment":34},{"nctId":"NCT02944500","phase":"PHASE4","title":"Saxenda: Underlying Mechanisms and Clinical Outcomes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Obesity","enrollment":28},{"nctId":"NCT03158805","phase":"PHASE2","title":"Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)","status":"COMPLETED","sponsor":"Lindner Center of HOPE","startDate":"2017-04-26","conditions":"Bipolar Disorder, Obesity","enrollment":60},{"nctId":"NCT06818292","phase":"NA","title":"Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists","status":"COMPLETED","sponsor":"Nils Opel","startDate":"2024-10-21","conditions":"Healthy","enrollment":10},{"nctId":"NCT05268237","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus","status":"RECRUITING","sponsor":"Biolingus","startDate":"2023-04-25","conditions":"Diabete Type 2","enrollment":15},{"nctId":"NCT05794581","phase":"PHASE1","title":"A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes","status":"COMPLETED","sponsor":"Carmot Therapeutics, Inc.","startDate":"2023-03-21","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT06726577","phase":"PHASE1, PHASE2","title":"TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis","status":"RECRUITING","sponsor":"Talengen Institute of Life Sciences, Shenzhen, P.R. China.","startDate":"2024-12-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":60},{"nctId":"NCT06361238","phase":"PHASE3","title":"Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-11-19","conditions":"Delirium, Postoperative","enrollment":260},{"nctId":"NCT03555994","phase":"PHASE2","title":"A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2018-05-31","conditions":"Type 2 Diabetes Mellitus","enrollment":51},{"nctId":"NCT04199728","phase":"PHASE1, PHASE2","title":"Use of a GLP-1R Agonist to Treat Opioid Use Disorder","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2021-10-18","conditions":"Opiate Substitution Treatment, Opioid-Related Disorders","enrollment":27},{"nctId":"NCT03115424","phase":"PHASE3","title":"Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-06-22","conditions":"Obesity","enrollment":46},{"nctId":"NCT04763564","phase":"PHASE2","title":"Efficacy of Liraglutide Therapy in Patients With IPAA","status":"TERMINATED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-03-22","conditions":"Pouchitis, Irritable Pouch Syndrome","enrollment":8},{"nctId":"NCT02403284","phase":"PHASE4","title":"The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans","status":"COMPLETED","sponsor":"Phoenix VA Health Care System","startDate":"2013-03","conditions":"Insulin Resistance","enrollment":97},{"nctId":"NCT03856047","phase":"PHASE2","title":"Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-03-01","conditions":"Overweight, Obesity","enrollment":706},{"nctId":"NCT04311411","phase":"PHASE1","title":"A Study of Tirzepatide in Overweight and Very Overweight Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-08-24","conditions":"Obesity, Overweight","enrollment":114},{"nctId":"NCT02953665","phase":"PHASE2","title":"Safety and Efficacy of Liraglutide in Parkinson's Disease","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2017-04-03","conditions":"Parkinson Disease","enrollment":63},{"nctId":"NCT03672812","phase":"PHASE3","title":"The Use of Liraglutide in Brain Death","status":"COMPLETED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2018-09-01","conditions":"Brain Death","enrollment":50},{"nctId":"NCT02777073","phase":"NA","title":"Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2016-03-01","conditions":"Type 1 Diabetes","enrollment":43},{"nctId":"NCT01509742","phase":"PHASE1","title":"Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":19},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT01722240","phase":"PHASE3","title":"Liraglutide in Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":69},{"nctId":"NCT01722266","phase":"PHASE3","title":"Liraglutide in the Treatment of Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-11-01","conditions":"Type 1 Diabetes","enrollment":72},{"nctId":"NCT04324229","phase":"NA","title":"Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Turku University Hospital","startDate":"2020-02-07","conditions":"Gestational Diabetes","enrollment":80},{"nctId":"NCT03795701","phase":"NA","title":"To Predict Weight Loss Response to Liraglutide (Saxenda®), From fMRI-based Determination of Food Cue Reactivity","status":"COMPLETED","sponsor":"Texas Tech University","startDate":"2019-01-08","conditions":"Obesity","enrollment":73},{"nctId":"NCT01508949","phase":"PHASE2","title":"Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2001-06","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":35},{"nctId":"NCT01507285","phase":"PHASE1","title":"Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"1999-08","conditions":"Diabetes, Diabetes Mellitus, Type 2, Healthy","enrollment":24},{"nctId":"NCT03712098","phase":"PHASE2","title":"Daily Liraglutide for Nicotine Dependence","status":"COMPLETED","sponsor":"Rebecca Ashare","startDate":"2018-11-29","conditions":"Smoking Cessation, Weight, Body","enrollment":40},{"nctId":"NCT03757130","phase":"PHASE1","title":"Multiple Ascending Dose Study of AMG 598 in Adults With Obesity","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-11-26","conditions":"Obesity","enrollment":50},{"nctId":"NCT02527200","phase":"PHASE3","title":"Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-09","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":56},{"nctId":"NCT04605861","phase":"PHASE3","title":"The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2020-08-18","conditions":"Obese, Overweight","enrollment":414},{"nctId":"NCT04074161","phase":"PHASE3","title":"Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2019-09-11","conditions":"Overweight, Obesity","enrollment":338},{"nctId":"NCT01779362","phase":"PHASE3","title":"RISE Adult Medication Study","status":"COMPLETED","sponsor":"RISE Study Group","startDate":"2013-04","conditions":"Prediabetes, Type 2 Diabetes","enrollment":267},{"nctId":"NCT05444569","phase":"PHASE1","title":"A Study of LY3537021 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-08","conditions":"Healthy","enrollment":47},{"nctId":"NCT03048578","phase":"PHASE4","title":"Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2017-05-22","conditions":"Obesity","enrollment":132},{"nctId":"NCT03101930","phase":"PHASE4","title":"Cardiovascular Effects of GLP-1 Receptor Activation","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2017-05-01","conditions":"Obesity, PreDiabetes","enrollment":329},{"nctId":"NCT04903509","phase":"PHASE1","title":"A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With Liraglutide","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2021-06-08","conditions":"Healthy","enrollment":95},{"nctId":"NCT02344186","phase":"PHASE4","title":"Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes","status":"UNKNOWN","sponsor":"Temple University","startDate":"2014-05","conditions":"Type 2 Diabetes","enrollment":12},{"nctId":"NCT02863419","phase":"PHASE3","title":"Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-08-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":711},{"nctId":"NCT02417103","phase":"PHASE3","title":"Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid","status":"TERMINATED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2011-12","conditions":"Obesity","enrollment":2},{"nctId":"NCT03523273","phase":"PHASE2","title":"Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity","status":"COMPLETED","sponsor":"Michael Camilleri, MD","startDate":"2017-11-29","conditions":"Obesity","enrollment":136},{"nctId":"NCT03955575","phase":"PHASE4","title":"Treatment of Bile Acid Malabsorption With Liraglutide","status":"COMPLETED","sponsor":"Filip Krag Knop","startDate":"2019-03-07","conditions":"Bile Acid Malabsorption","enrollment":52},{"nctId":"NCT05360147","phase":"PHASE3","title":"Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2021-01-20","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT02765399","phase":"PHASE4","title":"The Effect of Liraglutide Treatment on Postprandial Chylomicron and VLDL Kinetics, Liver Fat and de Novo Lipogenesis","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2015-02-01","conditions":"Type 2 Diabetes","enrollment":23},{"nctId":"NCT02973321","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-02","conditions":"Type 2 Diabetes Mellitus","enrollment":296},{"nctId":"NCT01982630","phase":"PHASE1","title":"Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-11-07","conditions":"Diabetes Mellitus","enrollment":87},{"nctId":"NCT02898506","phase":"PHASE2","title":"Incretin-based Therapy in Late Preclinical Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT02611232","phase":"PHASE2","title":"Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults","status":"UNKNOWN","sponsor":"University of Oulu","startDate":"2015-12","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT02908087","phase":"PHASE2","title":"Incretin-based Therapy in Early Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT03038620","phase":"PHASE4","title":"Impact of Liraglutide 3.0 on Body Fat Distribution","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-01","conditions":"Obesity, Visceral, Cardiovascular Diseases, Fat Disorder","enrollment":235},{"nctId":"NCT02138045","phase":"NA","title":"Treatment of Diabetic Neuropathy With Liraglutide","status":"COMPLETED","sponsor":"Aalborg University Hospital","startDate":"2014-05","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus","enrollment":39},{"nctId":"NCT01541215","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2012-11-13","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":135},{"nctId":"NCT03480022","phase":"PHASE3","title":"Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS","status":"COMPLETED","sponsor":"Woman's","startDate":"2018-09-26","conditions":"Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android","enrollment":88},{"nctId":"NCT03347890","phase":"PHASE4","title":"Reward Mechanisms in Obesity","status":"COMPLETED","sponsor":"Zoltan Pataky","startDate":"2018-03-05","conditions":"Obesity","enrollment":70},{"nctId":"NCT02443155","phase":"PHASE2","title":"A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-11-10","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":308},{"nctId":"NCT01879917","phase":"PHASE2, PHASE3","title":"Liraglutide in Newly Onset Type 1 Diabetes.","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2014-02","conditions":"Diabetes Mellitus, Type 1","enrollment":65},{"nctId":"NCT03466021","phase":"PHASE4","title":"Effects of Liraglutide in Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Claus Bogh Juhl","startDate":"2018-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":40},{"nctId":"NCT04057261","phase":"PHASE3","title":"Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease","status":"WITHDRAWN","sponsor":"RWTH Aachen University","startDate":"2020-11","conditions":"Type 2 Diabetes, Cardiovascular Diseases","enrollment":""},{"nctId":"NCT02889510","phase":"PHASE3","title":"Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Lecube, Albert, M.D.","startDate":"2016-10-04","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT02299388","phase":"PHASE4","title":"To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study","status":"COMPLETED","sponsor":"Tulane University School of Medicine","startDate":"2014-10","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Hypertensive Disease","enrollment":11},{"nctId":"NCT03018028","phase":"PHASE3","title":"Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-01-10","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":243},{"nctId":"NCT02655770","phase":"PHASE4","title":"Effect of Liraglutide on Diastolic Dysfunction on Cardiac MRI in Type 2 Diabetes Patients","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2016-02","conditions":"Diabetes Mellitus Type 2, Diastolic Dysfunction, Cardiac MRI","enrollment":40},{"nctId":"NCT03279731","phase":"PHASE3","title":"Binge Eating Liraglutide Intervention","status":"TERMINATED","sponsor":"Kelly Allison","startDate":"2017-09-29","conditions":"Binge-Eating Disorder","enrollment":36},{"nctId":"NCT02964247","phase":"PHASE3","title":"LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-03-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":303},{"nctId":"NCT02617654","phase":"PHASE2","title":"Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes","status":"COMPLETED","sponsor":"Per-Ola Carlsson","startDate":"2015-11","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT03341429","phase":"PHASE4","title":"Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response","status":"COMPLETED","sponsor":"University College, London","startDate":"2018-08-22","conditions":"Obesity","enrollment":70},{"nctId":"NCT01795248","phase":"PHASE4","title":"The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes","status":"COMPLETED","sponsor":"Tina Vilsboll","startDate":"2012-07","conditions":"Gestational Diabetes Mellitus","enrollment":105},{"nctId":"NCT04122716","phase":"PHASE4","title":"Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet","status":"UNKNOWN","sponsor":"Signe Torekov","startDate":"2016-09","conditions":"Obesity","enrollment":215},{"nctId":"NCT04525300","phase":"PHASE3","title":"Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-24","conditions":"Obesity","enrollment":300},{"nctId":"NCT03235050","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-08-02","conditions":"Diabetes Mellitus, Type 2","enrollment":834},{"nctId":"NCT04487743","phase":"PHASE3","title":"Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2020-05-09","conditions":"Obesity","enrollment":300},{"nctId":"NCT02205528","phase":"PHASE2","title":"A Study of Once-Daily NNC0090-2746 in Participants With Type 2 Diabetes Inadequately Controlled With Metformin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2014-08-18","conditions":"Diabetes, Diabetes Mellitus Type 2","enrollment":108},{"nctId":"NCT03449654","phase":"PHASE4","title":"Effect of Liraglutide on Vascular Inflammation in Type-2 Diabetes","status":"COMPLETED","sponsor":"Steno Diabetes Center Copenhagen","startDate":"2017-10-26","conditions":"Diabetes Mellitus, Type 2","enrollment":102},{"nctId":"NCT02650206","phase":"PHASE1","title":"Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood","status":"COMPLETED","sponsor":"Stanford University","startDate":"2015-01","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus, Type II, Diabetes Mellitus, Adult-Onset","enrollment":56},{"nctId":"NCT02918279","phase":"PHASE3","title":"Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2016-09-29","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":251},{"nctId":"NCT02453711","phase":"PHASE2","title":"Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-10-01","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":957},{"nctId":"NCT02963922","phase":"PHASE3","title":"Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-02-06","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":396},{"nctId":"NCT04325581","phase":"PHASE3","title":"Laparocopic Sleeve Gastrectomy With or Without Liraglutide in Obese Patients","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2016-08-01","conditions":"Weight Loss","enrollment":16},{"nctId":"NCT02963935","phase":"PHASE3","title":"Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2017-02-06","conditions":"Metabolism and Nutrition Disorder, Obesity","enrollment":282},{"nctId":"NCT02351232","phase":"PHASE2, PHASE3","title":"The Lira Pump Trial","status":"COMPLETED","sponsor":"Hvidovre University Hospital","startDate":"2015-02","conditions":"Type 1 Diabetes","enrollment":44},{"nctId":"NCT03486392","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-03-26","conditions":"Obesity","enrollment":474},{"nctId":"NCT01753362","phase":"PHASE3","title":"Liraglutide In Overweight Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2012-12","conditions":"Type 1 Diabetes","enrollment":84},{"nctId":"NCT04046822","phase":"PHASE4","title":"Effect of Liraglutide on Microbiome in Obesity","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2019-01-09","conditions":"Obesity, Weight Loss, Microbiome","enrollment":70},{"nctId":"NCT00696657","phase":"PHASE2","title":"A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-06-03","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":415},{"nctId":"NCT02461589","phase":"PHASE2","title":"Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2015-09-21","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":706},{"nctId":"NCT03041792","phase":"PHASE1","title":"Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-02-20","conditions":"Obesity","enrollment":61},{"nctId":"NCT01234649","phase":"PHASE3","title":"Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)","status":"COMPLETED","sponsor":"Woman's","startDate":"2011-08-11","conditions":"Gestational Diabetes Mellitus, Type 2 Diabetes Mellitus, Metabolic Syndrome","enrollment":153},{"nctId":"NCT01179048","phase":"PHASE3","title":"Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2010-08-31","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":9341},{"nctId":"NCT03707171","phase":"PHASE3","title":"Effects of Liraglutide on the Cognitive Function in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Third Military Medical University","startDate":"2018-10-01","conditions":"Type 2 Diabetes Mellitus","enrollment":30},{"nctId":"NCT04008290","phase":"PHASE4","title":"The Effect of Liraglutide on the GIT","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-04-01","conditions":"Obesity","enrollment":15},{"nctId":"NCT01843075","phase":"PHASE2","title":"Evaluating Liraglutide in Alzheimer's Disease","status":"UNKNOWN","sponsor":"Imperial College London","startDate":"2014-01","conditions":"Alzheimer's Disease","enrollment":204},{"nctId":"NCT02911818","phase":"PHASE4","title":"Lifestyle Modification and Liraglutide","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2016-09","conditions":"Obesity","enrollment":150},{"nctId":"NCT02928471","phase":"","title":"Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":200},{"nctId":"NCT02910570","phase":"PHASE4","title":"Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis","status":"COMPLETED","sponsor":"Parker Research Institute","startDate":"2016-11","conditions":"Osteoarthritis, Knee","enrollment":150},{"nctId":"NCT02905864","phase":"PHASE4","title":"Liraglutide 3 mg for Knee Osteoarthritis","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150},{"nctId":"NCT02928679","phase":"PHASE4","title":"Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Maintenance","status":"COMPLETED","sponsor":"Henrik Gudbergsen","startDate":"2016-11","conditions":"Osteoarthritis, Obesity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Isotonic saline"],"phase":"marketed","status":"active","brandName":"Placebo-liraglutide","genericName":"Placebo-liraglutide","companyName":"University of Aarhus","companyId":"university-of-aarhus","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}